(QEPE) ON THE CENTRAL NERVIOUS SYSTEM (BRAIN) OF NEWBORN BALB/C MICE

Nasim Javdan, Jasem Estakhr

Science and Research Branch, Islamic Azad University, Fars, Iran.

Corresponding Address: Nasim Javdan, n j222222@yahoo.com Tel: +989153400715.

Summary

This study aim to investigate effects of 4(3H)quinazlonones-2-ethyl-2-phenyl ethyl (QEPE) as a new

quinazolinone on brain development of newborn Balb/C mice. Pregnant Balb/C mice (n=8) were

divided into 3 groups of control, receiving distilled water, sham, treated with 0.05% methyl cellulose

(the solvent)and experimental group, receiving one of the most effective dose of 100mg/kg/body

weight of 4(3H)quinazlonones-2-ethyl-2-phenyl ethyl (QEPE), by IP injections on days 8th to 15th of

gestation. After anesthetizing, brains of 5-day old newborn Balb/C mice were removed and

prepared for histopathological studies. Data demonstrated an increase in the number of astrocytes

of cerebral cortex and medulla of newborn mice of treated groups. Confirming the results, statistical

studies showed no significant differences between the morphology of newborn mice of control,

sham and treated groups'astrocytes, but there were significant differences in the number of

astrocytes of newborn mice of group treated with QEPE. In conclusion, astrocyte hyperplasia

decreases toxic effects of QEPE by passing through blood-brain barrier.

Keywords: 4(3H)quinazlonones-2-ethyl-2-phenyl ethyl (QEPE), Brain, Balb/C mice.

911

Introduction

During the past few decades, it has become increasingly evident that human and animal embryos are subjected to a variety of environmental influences and drugs that could have deleterious effects on their development (1-3). Since the thalidomide tragedy, attention has been focused on drugs or chemicals as potential teratogen, to which pregnant women might be exposed (4-6). Quinazolinones are heterocyclic and water insoluble compounds (7), with various pharmacological; antimicrobial, antifungal, antifumor, anticonvulsant, anti-inflammatory, antiallergy, antimalaria (8-14). They are more efficient than other chemicals in inhibiting HIV and cancer (15, 16). The mechanism of the effects of quinazolinones on the embryonic cells is not clear yet, but there are quite a few reports showing its toxic characteristics. They inhibit polymerization of tubulin (17) and pass through placental barriers (18), so there is a possibility that it has some sort of toxic and teratogenic effects on embryos. Previous studies at the Department of Zoology, Faculty of Biological Science, University of Shahid-Beheshti, 4(3H)quinazlonones-2-ethyl-2-phenyl ethyl (QEPE) can cause morphological, skeletal and histological abnormalities in Balb/C mice embryos. In the present study we interested that whether treatments pregnant mice with QEPE would affect the brain development of Balb/C mouse fetuses.

Materials and Methods

Balb/C mice were housed in 24±1° C ,65 ± 0.5% humidity and lighted controlled room (12h light-dark), provided with lab chow (pellets) and tap water. They were originally obtained from Razi Institute (Tehran, Iran); Random breedings were implemented in our local facility, animal room, with breeding, operation and maintenance sections. Males mated virgin females at overnight, observing vaginal plugs presented day zero of pregnancy. The new derivative of qunazolinones: 4(3H)quinazlonones-2-ethyl-2-phenyl ethyl (QEPE), synthesized at Department of Chemistry,

Faculty of Science, University of Shahid-Beheshti, Tehran, Iran were used for IP injection. So, pregnant mice were divided into 3 groups (n=10) of control, sham, and experimental, received distilled water (10ml/kg), methyl cellulose %0.05 (10ml/kg) (the solvent of quinazolinones) and 100 mg/kg Balb/C body weight of QEPE (most effective dose), respectively, by IP injection, on days 8th to 15th of gestation. 5day old newborns were killed by cervical dislocation. The brain was excised from each mouse and measured in weight. Then they were fixed in formalin %10, stained with H&E (Hematoxilin & Eosine) for histological and pathological studies under compound microscope. Data were analyzed with statistical packages for social sciences (SPSS,version 12.0). Mean and standard error of mean [SEM] were calculated and the significance of difference was analyzed by applying One-Way ANOVA. Level of significance difference was P<0.05.

Results:

Results showed increase in the diameters of cerebral microglia of newborn Balb/C mice brains of mothers treated with QEPE. Abnormal myelin sheaths were observed in newborn Balb/C mice of mothers treated with QEPE.

Statistical analysis showed significant differences (P<0. 05) between the number of astrocytes of newborn Balb/C mice cerebral cortex and medulla of 3 different groups and QEPE increased these factors in the brain of experimental group.

Figure 1: Effect of QEPE in diameters of cerebral microglia of newborn Balb/C mice. (P<0.05).





Figure 2: Effect of QEPE on the number of abnormal myelin sheaths of newborn Balb/C mice. (P<0.05).



Pharmacologyonline 2: 911-918 (2011)

Newsletter

Javdan and Estakhr

Figure 3: Effect of QEPE on the mean number of astrocytes of newborn Balb/C. (P<0.05).





Figure 4: Increase in the mean number of astrocytes of newborn Balb/C treated with QEPE. .

(P<0.05).



Discussion

Quinazolinones are heterocyclic, water insoluble and lipophilic compounds, with various pharmacological characteristics; (antimicrobial, antifungal, antiswelling, Parkinson and etc.) (7-14).

They are more efficient than other chemicals in inhibiting HIV and cancer (15-17). They enter circulatory system and passes through placental barrier (18). In current study, there was no significant difference between brain of control and sham groups, indicating methyl cellulose 0/05% (the solvent) had no teratogenic effects on newborn mice. Results of this investigation proved that quinazolinones pass through placenta barrier, affecting brain and other organs. In response to QEPE treatments, astrocytic hyperplasia was observed in the brains of newborn Balb/C mice, so that their processes, surrounding synapses with efficient uptake systems, removed excitatoxins; There are growing evidences suggesting that astrocytes play critical role in the regulation of excitatoxicity and inflammatory processes during evolution of Alzheimer's disease (19). Neurons are not injured because of astrocytes' involvement in homeostasis of CNS, regulating ionic and water balances, anti-oxidant concentrations, uptake and metabolism of neurotransmitters, and sequestration of potential neurotoxins(ammonia, heavy metals, and excitatory amino acid neurotransmitters such as glutamate and aspirate) (20, 21). Previous investigations indicated that IL-6, released from astrocytes, corresponded with gliosis, inducing FGF from astrocytes (22, 23). On the other hand, QEPE enters the brain as antigen, causing release of chemotaxics from macrophages. Thereafter, macrophages produce lysozymal enzymes, chemical mediatores and free radicals which would not bring about severe swellings, however, as in our experiments, brain could repair itself (24).

References

- (1) Houghten R.A., Ostresh J.M. Synthesis of quinazolinone libraries and derivatives thereof. United States Patent 19985783577.
- (2) Mhaske S.B., Narshinha P., Argade N.P. The chemistry of recently isolated naturally occurring quinazolinone alkaloids. Tetrahedron 2006;62(42):9787-826.

- (3) Refaie F.M., Esmat A.Y., Abdel Gawad S.M., Ibrahim A.M., Mohamed M.A. The antihyperlipidemic activities of 4(3H)quinazolinone and two halogenated derivatives in rats. Lip. Health Dis. 2005;4: 22-30.
- (4) Corbett J.W.,Ko S.S.,Rodgers J.D.,Jeffrey S.,Bacheler L.T.,Klabe R.M.,Diamond S., Lai C.M.,Rabel S.R.,Saye J.A.,Adams S.P.,Trainor G.L.,Anderson P.S., Erickson-Viitanen S.K. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicr. Agents Chem. 1999;43(12),2893-897.
- (5) Sperandio DaSilva G.M., Sant'Anna C.M.R., Barreiro E.J. A novel 3D-QSAR comparative molecular field analysis(CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors. Bio. Med. Chem. 2004;12(12):3159-166.
- (6) Pelletier S.W.Alkaloids:chemical and biological prospectives. Wiley & Sons Ltd. 1983; NY, USA.
- (7) XiaY., Yang Z.Y., Hour M.J., Kuo S.C., Xia P., Bastow K.F., Nakanishi Y., Nampoothiri P., Hackl T., Hamel E., Lee K.H. Anti-tumor agents. Part 204: Synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bio. Med. Chem . Lett. 2001;11(9): 1193-196.
- (8) Hour M.J., Huang L.J., Kuo S.C., Xia Y., Bastow K., Nakanishi Y., Hamel E., Lee K.H. 6-Alkylamino- and 2,3-Dihydro-3'-methoxy-2-phenyl-4-quinazolinones and related compounds: Their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem. 2000; 43 (23):4479–487.
- (9) Raffa D., Elder M.C., Daidone G., Maggio B., Merickech M., Plescia D., Bai R., Hamel E. Synthesis and cytotoxicity and inhibitory effect on tubulin polymerization of a new 3-heterocycle substituted 2-styryl quinazolinones. Eur. J. Med. Chem. 2004;39: 299-04.
- (10) Ishida J., Yamamoto H., KidoY., Kamijo K., Murano K., Miyake H., Ohkubo M., Kinoshita T., Warizaya M., Iwashita A., Mihara K., Matsuoka N., Hattori K. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling. Bio. Med. Chem. 2006;14(5):1378-390.
- (11) Griffin R.J., Srinivasan S., Bowman K., Calvert A.H., Curtin N.J., Newell D.R., Pemberton L.C., Golding B.T. Resistance-modifying agents. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP- ribose) polymerase (PARP). J. Med. Chem. 1998; 41 (26):5247–256.
- (12) Hattori K., Kido Y., Yamamoto H., Ishida J., Kamijo K., Murano K., Ohkubo M., Kinoshita T., Iwashita A., Mihara K., Yamazaki S., Matsuoka N., Teramura Y., Miyake H. Rational approaches to discovery

- of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase.J.Med.Chem. 2004;47(17):4151–154.
- (13) Scott G.S., Komj.ti K., Besson V.C., Szab. C. Role of poly(ADP-ribose)polymerase in brain inflammation and neuroinjury. Biomed. Life Sci. 2007; 3: 427-66.
- (14) Veres B.,Radnai B.,Gallyas F.Jr.,Varbiro G.,Berente Z.,Osz E., Sumegi B. Regulation of kinase cascades and transcription factors by a poly(ADP-ribose)polymerase-1 inhibitor,p4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J. Pharmacol. Exp. Ther. 2004;310(1):247-55.
- (15) Corbett J.W., Ko S.S. 4,4-distributed-3,4-dihydro-2(1H)-quinazolinones usefull as HIV reverse transcriptase inhibitors. Du Pont Pharmacol. Co. Legal Patent Res. Cen. 1998;28:25-31.
- (16) Rasmussen K., Yu M.J., Czachura J.F. Quinazolinone cholecystokinin(CCK)-B antagonists decrease midbrain dopamine unit activity. Syn . 1994;17(4):278-82.
- (17) Clark R.D., O'yang C. Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones and stress.Br. J. Pharmacol. 1995;5:781-78.
- (18) Ozaki K.I., Yamada Y., Oine T., Ishizuka T., Iwasawa Y. Studies on 4(1H)-quinazolinones. 5. Synthesis and anti-inflammatory activity of 4(1H)-quinazolinone derivatives. J. Med. Chem. 1985; 28 (5):568–76.
- (19) Ballaz S.J., Akil H., Watson S.J. The CCK-system mediates adaptation to novelty-induced stress in the rat: a pharmacological evidence. Neurosci. Lett. 2007; 428(1):27-32.
- (20) Santagati N., Bousquet E., Spadaro A., Ronsisvalle G. 4-quinazolinone synthesis and reduction of prostaglandin E2 production II. Farmacol. 1999;52:780-84.
- (21) Balbaa M., Abdel-Megeed M.Inhibition of mammalian aspartate transcarbamylase by quinazolinone derivatives. J. En. Int. Med. Chem., 2008;23(4):483 92.
- (22) Wang K., Kirichian A.M., Al Aowad A.F., Adelstein S.J., Kassis A.I. Evaluation of chemical, physical, and biological properties of tumor-targeting radioiodinated quinazolinone derivative. Bioconj. Chem. 2007; 18 (3):754–64.
- (23) Vergun O., Dineley K.E., Reynolds I.J. Ion transport and energy metabolism. Handbook Neurochem. Mol. Neurobiol. 2007;4(7): 429-65.
- (24) Dihne M.,Block F.,Korr H., Topper R. Time course of glial proliferation and glial apoptosis following excitotoxic CNS injury. Br. Res. 2001;902:178–89.